These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Total body irradiation etoposide followed by autologous hematopoietic stem cell transplantion for non-Hodgkin's lymphoma].
    Author: Shi Y, Lei Y, Zhou S.
    Journal: Zhonghua Yi Xue Za Zhi; 1998 Sep; 78(9):658-61. PubMed ID: 11038787.
    Abstract:
    OBJECTIVE: To evaluate the therapeutic effectiveness and safety of total body irradiation(TBI) and Etoposide(Vp-16) as a preparative regimen for autologous hematopoietic stem cell transplantation(AHSCT) with non-Hodgkin's lymphoma(NHL). METHODS: Twenty-four patients with intermediate and high grade NHL underwent AHSCT. They achieved complete remission (CR) or partial remission (PR) after induction chemoradiotherapy. Twenty-three patients had first CR or PR, and one third CR. Ten patients underwent autologous bone marrow transplantation (ABMT) and 14 autologous peripheral blood stem cell transplantation (APBSCT). The preparative regimen was TBI 800(700-850) cGy/Vp-16 757(323-1140) mg/m2. RESULTS: At a median follow-up of 22.5(2-92) months, the one-year disease free survival(DFS) was 86.7% (13/15), 3-year, 5-year and 7-year DFS were 80.0% (12/15) in patients with CR before AHSCT. The DFS was 66.7% (4/6) in patients with PR before AHSCT. The patients who had relapsed before AHSCT(3 cases) did not reach DFS. The hematopoietic function recovery was rapid in APBSCT than ABMT. CONCLUSION: The clinical results of AHSCT for intermediate and high grade NHL who achieved CR or PR after induction therapy are satisfactory. The TBI/Etoposide is an effective and safe preparative regimen for AHSCT in NHL patients.
    [Abstract] [Full Text] [Related] [New Search]